AdAlta Limited is a clinical stage drug discovery and development company using our i-body platform to go where antibodies cannot, developing novel protein and cell therapeutics against challenging drug targets. Our i-bodies are particularly suited to targeting targets such as GPCRs that challenge traditional antibodies and as building blocks for next generation cellular immunotherapies. We are headquartered in Melbourne, Australia.

We are offering:
1. First in class, Phase II ready anti-fibrotic drug AD-214 for licensing or co-development
2. i-body platform for co-discovery and sponsored discovery collaborations against partner targets
3. i-body programs for LPAR1, RANKL, AMA1 (malaria, babesia) for partnering

We are seeking:
1. IND ready (or beyond) cellular immunotherapies invented in Asia Pacific and targeting solid cancers and non-cancer indications for in-licensing